Lupus (Drug Development)

Results of Phase III Trial of GL701 for Lupus Presented

Published in Women's Health Weekly, May 5th, 1997

Genelabs Technologies, Inc. reports that a treatment response was observed in a group of women with clinically active systemic lupus erythematosus (SLE), which constituted the majority of patients enrolled in the company's first pivotal clinical trial for GL701 (DHEA).

The study, however, did not achieve statistical significance when all patients were included in the analysis, as an unexpectedly high response rate to placebo was observed among those patients with minimal or no disease activity at baseline. This Phase III trial was designed to show whether the use of GL701 in women with SLE would allow reduction in their steroid doses while maintaining stable or reduced...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1997-05-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry